Breaking Finance News

SunTrust reported on Ariad Pharm (NASDAQ:ARIA), bumping its target to $22.00 earlier today

SunTrust upped the price target of Ariad Pharm (NASDAQ:ARIA) to $22.00 stating a possible upside of 0.65%.

Yesterday Ariad Pharm (NASDAQ:ARIA) traded -1.69% lower at $13.36. Ariad Pharm’s 50-day moving average is $11.46 and its 200-day moving average is $8.65. With the last stock price up 54.48% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 5,225,457 shares of Ariad Pharm exchanged hands, down from an avg. trading volume of 5,545,660

Recent Performance Chart

Ariad Pharm (NASDAQ:ARIA)

Ariad Pharm has 52 week low of $4.37 and a 52 week high of $14.26 and has a market cap of $0.

In addition to SunTrust reporting its target price, a total of 8 firms have reported on the stock. The consensus target price is $9.00 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 5 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Ariad Pharm (NASDAQ:ARIA)

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *